Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Comparative genomic hybridization in a case of melanoma that loses expression of S100, HMB45, Melan A and tyrosinase in metastasis.

Guo R, Wang X, Chen J, Gillies E, Fung KM, Li S, Hassell LA.

Int J Clin Exp Pathol. 2013 Dec 15;7(1):468-73. eCollection 2014.

2.

A metastatic melanoma with an unusual immunophenotypic profile.

Gao Z, Stanek A, Chen S.

Am J Dermatopathol. 2007 Apr;29(2):169-71.

PMID:
17414440
3.

Microphthalmia transcription factor in the immunohistochemical diagnosis of metastatic melanoma: comparison with four other melanoma markers.

Miettinen M, Fernandez M, Franssila K, Gatalica Z, Lasota J, Sarlomo-Rikala M.

Am J Surg Pathol. 2001 Feb;25(2):205-11.

PMID:
11176069
5.

S100, HMB-45, and Melan-A negative primary melanoma.

Shinohara MM, Deubner H, Argenyi ZB.

Dermatol Online J. 2009 Sep 15;15(9):7.

PMID:
19930994
6.

Melan-A: not a helpful marker in distinction between melanoma in situ on sun-damaged skin and pigmented actinic keratosis.

El Shabrawi-Caelen L, Kerl H, Cerroni L.

Am J Dermatopathol. 2004 Oct;26(5):364-6.

PMID:
15365366
7.
8.

Expression of melanocytic differentiation markers in malignant melanomas of the oral and sinonasal mucosa.

Prasad ML, Jungbluth AA, Iversen K, Huvos AG, Busam KJ.

Am J Surg Pathol. 2001 Jun;25(6):782-7.

PMID:
11395556
9.

Chromosomal imbalances in primary and metastatic melanomas revealed by comparative genomic hybridization.

Balázs M, Adám Z, Treszl A, Bégány A, Hunyadi J, Adány R.

Cytometry. 2001 Aug 15;46(4):222-32.

PMID:
11514955
10.

Concordant loss of melanoma differentiation antigens in synchronous and asynchronous melanoma metastases: implications for immunotherapy.

Trefzer U, Hofmann M, Reinke S, Guo YJ, Audring H, Spagnoli G, Sterry W.

Melanoma Res. 2006 Apr;16(2):137-45.

PMID:
16567969
11.
12.

Immunophenotypic differences between uveal and cutaneous melanomas.

Iwamoto S, Burrows RC, Kalina RE, George D, Boehm M, Bothwell MA, Schmidt R.

Arch Ophthalmol. 2002 Apr;120(4):466-70.

PMID:
11934320
13.

Tyrosinase expression in malignant melanoma, desmoplastic melanoma, and peripheral nerve tumors.

Boyle JL, Haupt HM, Stern JB, Multhaupt HA.

Arch Pathol Lab Med. 2002 Jul;126(7):816-22.

PMID:
12088451
14.
15.

Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy.

Cormier JN, Abati A, Fetsch P, Hijazi YM, Rosenberg SA, Marincola FM, Topalian SL.

J Immunother. 1998 Jan;21(1):27-31.

PMID:
9456433
16.

Metastatic melanoma of the tongue: a case report with immunohistochemical profile.

Alves MG, Chagas LR, Carvalho YR, Cabral LA, Coletta RD, Almeida JD.

Gerodontology. 2014 Dec;31(4):314-9. doi: 10.1111/ger.12032.

PMID:
25427453
17.

Immunohistochemical expression of melanocytic antigen PNL2, Melan A, S100, and PGP 9.5 in equine melanocytic neoplasms.

Ramos-Vara JA, Frank CB, DuSold D, Miller MA.

Vet Pathol. 2014 Jan;51(1):161-6. doi: 10.1177/0300985812471545. Epub 2013 Jan 31.

PMID:
23370093
18.

Immunoprofile of MITF, tyrosinase, melan-A, and MAGE-1 in HMB45-negative melanomas.

Xu X, Chu AY, Pasha TL, Elder DE, Zhang PJ.

Am J Surg Pathol. 2002 Jan;26(1):82-7.

PMID:
11756773
19.
20.

Value of melanocytic-associated immunohistochemical markers in the diagnosis of malignant melanoma: a review and update.

Ordóñez NG.

Hum Pathol. 2014 Feb;45(2):191-205. doi: 10.1016/j.humpath.2013.02.007. Epub 2013 May 3. Review.

PMID:
23648379

Supplemental Content

Support Center